Burlington, Massachusetts, April 18, 2018 — MilliporeSigma today announced that its Millistak+® HC Pro portfolio has won an INTERPHEX Exhibitor Award for Best Technological Innovation.
“MilliporeSigma is dedicated to delivering innovations that bring advanced drug therapies to market, faster,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma. “As the first fully synthetic depth filters, MilliporeSigma’s Millistak+® HC Pro portfolio provides as much as twice the filtration capacity as commercial diatomaceous earth (DE)-based benchmarks and offers customers greater productivity and speed with reduced risk. We are honored to be recognized for this advancement in biopharmaceutical manufacturing.”
MilliporeSigma’s Millistak+® HC Pro portfolio is a family of synthetic depth filters providing cleaner, more consistent depth filtration media than other DE- and cellulose-based filter offerings. Made with entirely synthetic materials, Millistak+® HC Pro filters eliminate naturally derived components from the clarification process, resulting in increased productivity with less flushing.
MilliporeSigma’s Process Solutions business unit provides the industry’s most comprehensive portfolio of high-quality products and services for biopharmaceutical manufacturing.
For biopharmaceutical manufacturers, MilliporeSigma’s depth filter reduces total organic carbon extractables and pre-use flush volume by 50 percent. The filter also eliminates the potential for beta glucans, which can interfere with limulus amebocyte lysate testing used to detect and quantify bacterial endotoxins. The unparalleled lot-to-lot consistency helps biopharmaceutical manufacturers design a more robust clarification process.
MilliporeSigma is showcasing this industry-leading portfolio at Booth 2841 at INTERPHEX, which runs through tomorrow at the Javits Center, New York City.
For more information on MilliporeSigma’ Millistak+® HC Pro, visit www.emdmillipore.com/Millistak+HCPro.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 20,000 employees and 60 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA, Darmstadt, Germany, the vibrant science and technology company, operates across healthcare, life science and performance materials. Around 51,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2017, Merck KGaA, Darmstadt, Germany generated sales of €15.3 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.